See more : Cognex Corporation (CGNX) Income Statement Analysis – Financial Results
Complete financial analysis of Ventyx Biosciences, Inc. (VTYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ventyx Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Playground Ventures Inc. (PLAY.CN) Income Statement Analysis – Financial Results
- Wai Chun Bio-Technology Limited (0660.HK) Income Statement Analysis – Financial Results
- AMSKY Technology Co., Ltd (300521.SZ) Income Statement Analysis – Financial Results
- DATATRAK International, Inc. (DTRK) Income Statement Analysis – Financial Results
- Tesla, Inc. (TSLA) Income Statement Analysis – Financial Results
Ventyx Biosciences, Inc. (VTYX)
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 941.00K | 470.00K | 30.00K | 0.00 | 0.00 |
| Gross Profit | -941.00K | -470.00K | -30.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 175.77M | 87.74M | 58.48M | 6.37M | 3.55M |
| General & Administrative | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Other Expenses | 0.00 | 41.00K | -5.45M | -1.00K | -1.00K |
| Operating Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Cost & Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Interest Income | 15.07M | 4.67M | 78.00K | 358.00 | 146.00 |
| Interest Expense | 0.00 | 0.00 | 99.00K | 358.00K | 146.00K |
| Depreciation & Amortization | 158.00K | 470.00K | 30.00K | 7.05M | 4.18M |
| EBITDA | -207.84M | -107.96M | -67.12M | 0.00 | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.99M | -113.14M | -67.15M | -7.05M | -4.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.03M | 4.71M | -16.60M | -21.12M | -147.00K |
| Income Before Tax | -192.96M | -108.43M | -83.75M | -28.17M | -4.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -470.00K | -5.38M | 358.00K | 146.00K |
| Net Income | -192.96M | -107.96M | -78.37M | -28.53M | -4.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| EPS Diluted | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| Weighted Avg Shares Out | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
| Weighted Avg Shares Out (Dil) | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky Reminds Ventyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX
Levi & Korsinsky Reminds Ventyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) - April 30, 2024 Deadline to Join - Contact Levi & Korsinsky
Source: https://incomestatements.info
Category: Stock Reports